Fremanezumab for the Treatment of Migraine and Major Depressive Disorder
JAMA Neurology Author InterviewsShow Notes
Interview with Richard B. Lipton, MD, author of Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. Hosted by Cynthia E. Armand, MD.
Related Content: Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder
More from JAMA Neurology Author Interviews
Interview with Anick Bérard, PhD, author of Early Pregnancy Use of Anti-CGRP Monoclonal Antibodies and Propranolol and Spontaneous Abortion Risk. Hosted by Cynthia Armand, MD.
Interview with Prof Zheng-Ming Chen, DPhil author Smoking, Exhaled Carbon Monoxide, and Risk of Parkinson Disease. Hosted by Cynthia E. Armand, MD.
Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD.
Interview with Joseph T. Colonel, PhD, author Acoustic Analysis of Primary Care Patient–Clinician Conversations to Screen for Cognitive Impairment. Hosted by Cynthia E. Armand, MD.
Interview with Alessandra Fanciulli, MD, PhD, and Eduardo de Pablo-Fernández, MD, PhD, authors of Phenoconversion in Pure Autonomic Failure: A Systematic Review and Meta-Analysis. Hosted by Cynthia E. Armand, MD.